Page 101 - 《中国药房》2024年21期
P. 101

Medical Dictionary For Regulatory Activities and its use  Clin,2018,31(3):3899-3900.
              [J]. Chin J Pharmacovigil,2022,19(1):74-78.    [15]  罗世书,屈杰,周楠,等. 289例单克隆抗体抗肿瘤药品不
          [ 5 ]  中华人民共和国卫生部.药品不良反应报告和监测管理                         良反应报告分析[J]. 中国药物警戒,2023,20(4):444-448.
              办 法 [EB/OL].(2011-05-04)[2024-08-12].  https://www.  LUO  S  S,QU  J,ZHOU  N,et  al.  289  cases  of  adverse
              gov.cn/gongbao/content/2011/content_2004739.htm.    drug reactions associated with monoclonal antibody antitu‐
              National  Health  Commission  of  the  PRC.  Management   mor drugs[J]. Chin J Pharmacovigil,2023,20(4):444-448.
              measures for adverse drug reaction reporting and monito-   [16]  刘小林,符一岚,朱秋燕,等. 曲妥珠单抗致不良反应分
              ring[EB/OL]. (2011-05-04)[2024-08-12].  https://www.  析[J]. 药学与临床研究,2017,25(1):63-66.
              gov.cn/gongbao/content/2011/content_2004739.htm.    LIU X L,FU Y L,ZHU Q Y,et al. Clinical analysis of ad‐
          [ 6 ]  国家药品监督管理局药品审评中心.药物临床试验不良                         verse effects induced by trastuzumab[J]. Pharm Clin Res,
              事件相关性评价技术指导原则:试行[EB/OL].(2024-06-                   2017,25(1):63-66.
              07)[2024-08-12]. https://www. cde. org. cn/main/news/  [17]  胡康,孙素红,程晓明,等. 曲妥珠单抗致罕见过敏性反
              viewInfoCommon/0a5ae4924881321c07cce100e99f2a5c.    应一例并文献复习[J]. 中国肿瘤生物治疗杂志,2018,25
              National  Medical  Products  Administration  Drug  Evalua‐  (5):543-544.
              tion Center. Technical guidelines for adverse event correla‐  HU K,SUN S H,CHENG X M,et al. A case of trastu‐
              tion evaluation in drug clinical trials:trial[EB/OL].(2024-  zumab  for  rare  allergic  reaction  and  literature  review[J].
              06-07)[2024-08-12]. https://www.cde.org.cn/main/news/  Chin J Cancer Biother,2018,25(5):543-544.
              viewInfoCommon/0a5ae4924881321c07cce100e99f2a5c.  [18]  王聪,杨美凤,赵倩馨,等. 曲妥珠单抗致严重性过敏性
          [ 7 ]  谢伟,印慨. 人表皮生长因子受体2阳性胃癌靶向治疗的研                      反应一例[J]. 临床外科杂志,2023,31(6):600.
              究进展[J]. 中国肿瘤生物治疗杂志,2023,30(4):344-351.              WANG C,YANG M F,ZHAO Q X,et al. A case of se‐
              XIE W,YIN K. Research progress of targeted therapy for   vere  allergic  reaction  caused  by  trastuzumab[J].  J  Clin
              human epidermal growth factor receptor 2 positive gastric   Surg,2023,31(6):600.
              cancer[J]. Chin J Cancer Biother,2023,30(4):344-351.  [19]  毕亮亮,韩若凌,焦子义. 曲妥珠单抗相关不良反应的监测
          [ 8 ]  陈智翔. 曲妥珠单抗对HER2阳性晚期食管癌患者的疗                       及防治研究进展[J]. 医学研究与教育,2020,37(3):32-38.
              效观察[J]. 智慧健康,2022,8(4):123-126.                     BI  L  L,HAN  R  L,JIAO  Z Y. Advances  on  monitoring
              CHEN  Z  X.  Efficacy  of  trastuzumab  in  patients  with   prophylaxis and treatment trastuzumab related adverse re‐
              HER2  positive  advanced  esophageal  cancer[J].  Smart   actions[J]. Med Res Educ,2020,37(3):32-38.
              Healthc,2022,8(4):123-126.                     [20]  解染,赵楠,崔一民. 1例曲妥珠单抗致肝毒性的病例报
          [ 9 ]  周洁,车啸天. 曲妥珠单抗不良反应的特点及规律[J]. 山                    告及药物不良反应分析[J]. 中国临床药理学杂志,2017,
              西医药杂志,2021,50(2):196-198.                           33(10):936-938.
              ZHOU J,CHE X T. Characteristics and regularities of ad‐  XIE R,ZHAO N,CUI Y M. Trastuzumab-induced hepato‐
              verse  reactions  of  anti-tumor  targeted  drug  trastuzumab  toxicity and analysis of adverse drug reaction:a case re‐
              [J]. Shanxi Med J,2021,50(2):196-198.               port[J]. Chin J Clin Pharmacol,2017,33(10):936-938.
          [10]  吴海伟,白羽,刘红,等 . 我院 273 例抗肿瘤药物不良反               [21]  李亚佳,刘玲艳,杨平雄,等. 曲妥珠单抗对乳腺癌患者
              应报告分析[J]. 中国医药导报,2017,14(14):126-130.               肝毒性和胃肠道不良反应的 Meta 分析[J]. 云南医药,
              WU H W,BAI Y,LIU H,et al. Clinical analysis of 273   2023,44(4):58-65.
              adverse drug reaction reports of antineoplastics in our hos‐  LI Y J,LIU L Y,YANG P X,et al. Meta-analysis of he‐
              pital[J]. China Med Her,2017,14(14):126-130.        patic  toxicity  and  gastrointestinal  adverse  reactions  in
          [11]  VOGEL  C  L.  Efficacy  and  safety  of  trastuzumab  as  a   breast  cancer  patients  treated  with  trastuzumab[J].  Med
              single  agent  in  first-line  treatment  of  HER2-overexpres-   Pharm Yunnan,2023,44(4):58-65.
              sing  metastatic  breast  cancer[J].  J  Clin  Oncol,2002,20  [22]  曾慧,唐雪苗. 曲妥珠单抗在乳腺癌患者治疗中的心脏
              (3):719-726.                                        毒性[J]. 实用医学杂志,2017,33(12):2056-2058.
          [12]  WING  M.  Monoclonal  antibody  first  dose  cytokine  re‐  ZENG H,TANG X M. Cardiac toxicity of trastuzumab in
              lease  syndromes-mechanisms  and  prediction[J].  J  Immu‐  the  treatment  of  breast  cancer  patients[J].  J  Pract  Med,
              notoxicol,2008,5(1):11-15.                          2017,33(12):2056-2058.
          [13]  TABUCHI  Y,TSUJIMOTO  M,YAMAMOTO  K,et  al.   [23]  徐翠玉. 曲妥珠单抗在乳腺癌患者治疗中的心脏毒性分
              Risk factors for infusion reactions in patients with breast   析[J]. 世界复合医学,2020,6(7):164-166.
              cancer  administered  trastuzumab  therapy[J].  Biol  Pharm   XU C Y. Cardiotoxicity analysis of trastuzumab in breast
              Bull,2023,46(7):964-968.                            cancer  patients[J].  World  J  Complex  Med,2020,6(7):
          [14]  金小于. 乳腺癌患者应用曲妥珠单抗治疗的临床疗效与                         164-166.
              护理[J]. 当代临床医刊,2018,31(3):3899-3900.                           (收稿日期:2024-04-15  修回日期:2024-10-21)
              JIN X Y. Clinical efficacy and nursing care of breast can‐                          (编辑:胡晓霖)
              cer  patients  treated  with  trastuzumab[J].  Med  J  Present


          中国药房  2024年第35卷第21期                                              China Pharmacy  2024 Vol. 35  No. 21    · 2667 ·
   96   97   98   99   100   101   102   103   104   105   106